Why AstraZeneca Stock Topped the Market on Thursday

Core Insights - AstraZeneca's shares rose over 3% following a strong earnings report, contrasting with a 1.1% decline in the S&P 500 [1] Financial Performance - The company reported nearly $15.2 billion in revenue for Q3, a 12% increase compared to the same quarter in 2024, with notable growth in oncology (up 16%) and respiratory and immunology (up 13%) [2] - AstraZeneca's operating profit, not according to GAAP, increased by 16% to just under $5 billion, translating to $2.38 per share [3] - The earnings exceeded analyst expectations, with a consensus estimate of $1.22 per share for non-GAAP profitability and revenue expectations below $14.8 billion [4] Future Guidance - AstraZeneca reaffirmed its guidance for full-year 2025, anticipating revenue growth at a high-single-digit percentage rate and adjusted earnings per share growth at a low double-digit rate [5]